Nansha attracts 140 billion investments on AI, biotech and more

Guangzhou’s Nansha district has signed 73 projects with 140 billion RMB of investments at the 8th Annual Conference of International Investment which was held in Guangzhou on August 30.

These projects cover such fields as chip manufacturing, artificial intelligence, biomedicine, new energy, automobile manufacture, high-end equipment, marine science and technology, which show global investors’ perspective on Nansha’s development.

Wei Min, Executive Deputy Executive Chief of Nansha, said the district has the industrial base and aims to achieve a total industrial value of 2 thousand billion RMB by 2025.

He elaborated that Nansha focuses on the R&D and manufacture of chips, integrated circuits, strategic emerging industries, high-end equipment, intelligent products, and automobile manufacturing, as well as the marine economy.

In addition, Nansha launched 9 supportive policies for the commercial aerospace industry during the event, involving financing of enterprises, development of spacecraft, pre-launching preparation and orbit insertion, which covers the whole life cycle of commercial aerospace enterprises.

According to Nansha government, commercial aerospace enterprises will receive up to 100 million RMB subsidies for their R&D costs.

Zheng Jun, vice head of Guangzhou Zhongke aerospace company, said they have decided to settle in Nansha and commit to the basic research and scientific application, aiming to achieve the rocket industrialization as soon as possible.

“We will attract a batch of upstream and downstream companies in the industries, such as aerospace power R&D, satellite R&D, rocket and satellite measurement and control,” said Zheng.

As for biotechnology, Runer Ophthalmology, a renowned enterprise in the field of ophthalmology, announced their plan to invest in the construction of the headquarters, its R&D and production training base in Nansha, focusing on the ophthalmic diseases such as cataract, ocular inflammation, glaucoma and maculopathy. The project is expected to promote breakthroughs in biological innovative drugs in Nansha.